Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals

OBJECTIVE This study aimed to follow the natural progression of retinal changes in patients with diabetes. Such information should inform decisions with regard to the screening intervals for such patients. RESEARCH DESIGN AND METHODS An observational study was undertaken linking the data from seven diabetes retinal screening programs across the U.K. for retinal grading results between 2005 and 2012. Patients with absent or background retinopathy were followed up for progression to the end points referable retinopathy and treatable retinopathy (proliferative retinopathy). RESULTS In total, 354,549 patients were observed for up to 4 years during which 16,196 patients progressed to referable retinopathy. Of patients with no retinopathy in either eye for two successive screening episodes at least 12 months apart, the conditions of between 0.3% (95% CI 0.3–0.8%) and 1.3% (1.0–1.6%) of patients progressed to referable retinopathy, and rates of treatable eye disease were <0.3% at 2 years. The corresponding progression rates for patients with bilateral background retinopathy in successive screening episodes were 13–29% and up to 4%, respectively, in the different programs. CONCLUSIONS It may be possible to stratify patients for risk, according to baseline retinal criteria, into groups with low and high risk of their conditions progressing to proliferative retinopathy. Screening intervals for such diverse groups of patients could safely be modified according to their risk.

[1]  F. Ziemssen,et al.  Comment on Leese et al. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 2015;38:488–494 , 2015, Diabetes Care.

[2]  S. Taylor-Phillips,et al.  Extending the diabetic retinopathy screening interval beyond 1 year: systematic review , 2015, British Journal of Ophthalmology.

[3]  Max O Bachmann,et al.  Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England. Diabetes Care 2012;35:592–596 , 2014, Diabetes Care.

[4]  G. Roglić,et al.  Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[5]  A. Forster,et al.  Non-attendance at diabetic eye screening and risk of sight-threatening diabetic retinopathy: a population-based cohort study , 2013, Diabetologia.

[6]  J. Olson,et al.  Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme , 2013, Diabetologia.

[7]  Stephen J. Aldington,et al.  A Simple Risk Stratification for Time to Development of Sight-Threatening Diabetic Retinopathy , 2013, Diabetes Care.

[8]  D. R. Owens Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis , 2012, BMJ : British Medical Journal.

[9]  R V North,et al.  Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis , 2012, BMJ : British Medical Journal.

[10]  M. Bachmann,et al.  Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England , 2012, Diabetes Care.

[11]  C. Forsblom,et al.  Decline in the Cumulative Incidence of Severe Diabetic Retinopathy in Patients With Type 1 Diabetes , 2011, Diabetes Care.

[12]  E. Stefánsson,et al.  Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy , 2011, Diabetologia.

[13]  E. Agardh,et al.  Adopting 3-Year Screening Intervals for Sight-Threatening Retinal Vascular Lesions in Type 2 Diabetic Subjects Without Retinopathy , 2011, Diabetes Care.

[14]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[15]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[16]  P. Boyle,et al.  Screening Uptake in a Well-Established Diabetic Retinopathy Screening Program , 2008, Diabetes Care.

[17]  John D Ellis,et al.  Diabetic Retinopathy: More Patients, Less Laser , 2008, Diabetes Care.

[18]  E. Stefánsson,et al.  Biennial eye screening in patients with diabetes without retinopathy: 10-year experience , 2007, British Journal of Ophthalmology.

[19]  A. Morris,et al.  Implementation of national diabetes retinal screening programme is associated with a lower proportion of patients referred to ophthalmology , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[20]  J A Olson,et al.  The impact of the Health Technology Board for Scotland’s grading model on referrals to ophthalmology services , 2005, British Journal of Ophthalmology.

[21]  S. Harding,et al.  Incidence of sight‐threatening retinopathy in Type 1 diabetes in a systematic screening programme , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[22]  Simon P Harding,et al.  Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study , 2003, The Lancet.

[23]  Stephen J. Aldington,et al.  Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52) , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[24]  F. Ferris,et al.  Photocoagulation for diabetic macular edema. , 1987, Archives of ophthalmology.

[25]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. , 1987, Ophthalmology.

[26]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.

[27]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.

[28]  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. , 1985, Archives of ophthalmology.

[29]  S. Riaskoff Photocoagulation treatment of proliferative diabetic retinopathy. , 1981, Bulletin de la Societe belge d'ophtalmologie.